Myriad Genetics (NASDAQ:MYGN) Cut to “Market Perform” at Leerink Partners
Myriad Genetics (NASDAQ:MYGN – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, MarketBeat reports. They currently have a $21.00 target price on the stock, down from their prior target price of $30.00. Leerink Partners’ price […]
More Stories
Trump Says US Has Seized Oil Tanker Off Coast of Venezuela
By Jack Phillips President Donald Trump said on Dec. 10 that the United States seized an oil tanker off the...
Land Along Southern Border Is Transferred to Navy to Become Part of ‘National Defense Area’
By Jacob Burg The Trump administration said on Dec. 10 that it would transfer roughly 760 acres of public land...
We’ve Just Seen the Best Quarter in 3 Years (In Revenues) or 4 Years (Earnings)
By Louis Navellier I wrote this last weekend aboard the forty-fourth Forbes Cruise for Investors, where there was a high...
New Bipartisan Bills Aim to Raise Penalties for Online Child Abuse, Sextortion
By Savannah Hulsey Pointer Lawmakers announced on Dec. 9 three new bipartisan bills to address online violence and sexual abuse...
British Soldier Killed in Ukraine Watching Training Exercise
By Jill McLaughlin A British soldier was killed in Ukraine on Dec. 9 while watching a training exercise, the UK...
FDA Investigating Deaths Potentially Linked to COVID-19 Vaccines Across Age Ranges
By Aldgra Fredly The U.S. Food and Drug Administration (FDA) is looking into the potential links between COVID-19 vaccination and...